
Prominent US anti-vaxxer says he caught measles and traveled back home
Measles is a threat to people who are unvaccinated or immune-compromised. In anti-vaccine communities, it may quickly find a foothold and spread largely under the radar before ballooning into an outbreak.
Brian Hooker, chief scientific officer of Children's Health Defense, filmed an interview in west Texas in March with the parents of the six-year-old child who died from measles – the first measles death in the US in a decade.
The video promoted several dangerous myths about the measles, mumps, and rubella (MMR) vaccine. Two doses of the vaccine are 97% effective at preventing measles, a virus that can be deadly and can cause lifelong harm.
Hooker and Polly Tommey, an anti-vaccine film-maker with Children's Health Defense, also interviewed other Mennonite families in west Texas. And they visited the medical office of Ben Edwards while patients and Edwards himself had symptomatic measles, they said.
Hooker then traveled home to Redding, California, and developed measles symptoms, he said.
'Full disclosure, 18 days after visiting Seminole, Texas, sitting in a measles clinic and being exposed to Doctor Ben with the measles, I got the measles. So cool,' Hooker said.
Hooker, Tommey, and Edwards spoke on a podcast hosted by anti-vaccine activist Steve Kirsch on May 22. This news has not been previously reported by other outlets. Children's Health Defense did not respond to the Guardian's inquiry for this story.
Hooker doesn't appear to have sought healthcare or testing to confirm his symptoms were measles and not another infection. Other viral and bacterial infections may cause rashes, which is why medical providers need to conduct tests to confirm measles cases.
Without confirmation of his illness being measles, Hooker may spread misinformation about the illness – including what helps to treat it.
Hooker says he turned to the alternative treatments hailed by anti-vaccine activists. Edwards had given him cod liver oil and vitamin C supplements in Gaines county, Hooker said, noting: 'I stuck them in my luggage, and that's what I did.'
And if this case was measles, by not seeking confirmation testing and notifying officials, Hooker may have contributed to onward spread.
It's not clear if his first symptoms appeared after 18 days, or if he developed other symptoms – runny nose, cough, fever, watery eyes – and then a rash after 18 days.
After a person is exposed to measles, the virus usually incubates for 11 to 12 days before respiratory symptoms appear, followed by a rash two to four days later. A person is considered infectious four days before the rash appears and remains infectious until four days after it fades.
If Hooker's illness was measles, 'it sounds like my worst nightmare as an infectious disease doc,' said Peter Chin-Hong, professor of medicine and infectious disease specialist at University of California San Francisco. 'For all we know, there's a trail of measles, like bread crumbs in Hansel and Gretel.'
'For all we know, there's a trail of measles, like bread crumbs in Hansel and Gretel.'
In areas with no known cases, health providers might not immediately suspect measles, he said: 'Many people probably didn't know they had it. There could have been people who were ill with pneumonia, who went into the hospital and no one diagnosed it. It's very, very hard to diagnose because we haven't seen that much of it. But of course, we're seeing a lot more of it now.'
There are other indications that the actual number of cases from the Texas outbreak is higher than the official count, Chin-Hong said – with three confirmed deaths, experts might expect a case count closer to 3,000, instead of the 762 cases in Texas and 95 cases in New Mexico.
Typically, medical providers alert local or state health officials when a patient tests positive for measles. Health officials then conduct contact tracing to notify anyone who came into contact with the patient, including other travelers.
A representative for the Shasta county health department, serving the area where Hooker says he lives, said there have been no confirmed cases of measles reported this year.
'There are no cases of measles in Shasta county, and we have had no notice of any confirmed cases of measles this year,' said Jules Howard, community education specialist with the Shasta County Health & Human Services Agency.
It's important to know when a region has even a single case so resources can be diverted to the area to stop transmission, Chin-Hong said.
The most important part of those efforts is contact tracing and vaccinating anyone who is vulnerable – especially infants, pregnant people, and immune-compromised people, he said.
Hooker is a prominent figure in the anti-vaccine community. He testified on Tuesday before a US Senate committee in its first-ever 'vaccine injury' hearing, attempting to link MMR vaccination to autism – despite several studies showing no relationship.
Hooker said he became sick with measles despite being vaccinated as a child. But because he was born before 1989, he probably only received one dose of the MMR vaccine, which is 93% effective at stopping illness. Vaccination may also make breakthrough illness milder.
When anti-vaccine messages keep parents from getting their children vaccinated, 'I think the damage is immediate,' Chin-Hong said, before adding that it 'goes beyond the measles outbreak'.
Other vaccine-preventable illnesses like whooping cough and the flu are also surging.
'Measles is like the poster child, but it's about a way of life that we've taken for granted in the last few decades that is threatened,' Chin-Hong said. 'The fact that [they] are questioning it on a public stage means that a lot more people who might have trusted their clinicians are questioning it more now.'
The US eliminated measles in 2000, but the nation could lose that status if there is sustained transmission for more than a year.
'We're going back in time,' Chin-Hong said. 'We have to relearn all of these diseases.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Guardian
20 minutes ago
- The Guardian
What do we know about the Covid-19 virus five years on?
It's been five years since the start of the Covid pandemic. Although most of the government mandates, from social distancing to face masks, have been consigned to the past, the virus is still prevalent – and capable of causing real harm. Although it was initially forecast to become a seasonal illness, the virus is on the rise in the US – making it far from the common-cold-style winter illness that was expected. Experts told the Guardian a lot of predictions made about how Covid-19 would evolve have turned out to be wrong. Five years on, what do we know about the virus? Although news of a summer wave in the US has sparked fears it could be replicated in the UK, the latest data from the UK Health Security Agency shows that cases dropped by 28% over the past week to reach 1,046. Since most people don't test any more, this is unlikely to reflect the true prevalence. The data for the past year shows levels have remained consistent, with a large spike last October. Experts assumed that as Covid became endemic, it would change into a winter bug, like the common cold or flu. UKHSA stats show this is not the case. 'It is absolutely true that you are as likely to get Covid in summer as in winter,' said Danny Altmann, an immunologist at Imperial College London. He added: 'It's been a shifting discussion – when do we calm down and say it's become an endemic coronavirus like the common cold. I think we're still so far off that place. There's a kind of optimism that it's just a winter sniffle, but it's not a sniffle; it's quite symptomatic, especially in vulnerable people and in the excess death figures, and also it is absolutely not seasonal.' Altmann said that, although there is a perception that, as a coronavirus, Covid-19 is akin to a common cold, in reality it is closer to the flu in terms of the death rate, its impact on the NHS and the potential severity of symptoms. Simon Williams, a sociologist at Swansea University who has researched public views on the pandemic, said: 'We're getting to the point where there's a legitimate question about whether it will ever be [a winter virus]. It's not a typical respiratory virus in terms of seasonality.' Adam Kucharski, a professor at the London School of Hygiene & Tropical Medicine, said that because Covid-19 evolves quickly – twice as fast as the fastest flu – it is less constrained by season. 'Whereas a small change in transmissibility conditions is enough to stop flu in summer, Sars-CoV-2 can basically evolve its way over this barrier,' he said. The main Covid viruses in circulation are the Omicron subvariants. These are 'obviously milder than Wuhan or Delta', Altmann said, adding it's not the case that they are becoming progressively milder, but rather population immunity is higher due to vaccines and prior infections. The newest variant, NB.1.8.1, has been detected in the UK and international data suggests it is growing as a proportion of all Covid cases. World Health Organization analysis found the new strain is more contagious, but vaccination gives significant protection. Williams said we can expect to keep seeing the virus evolve, similar to how there are new flu virus combinations each year. The experts agreed the main problem is the low take-up of the free vaccine, which is available to people at greatest risk from Covid infection, including those aged 75 and over and those who are immunocompromised. Altmann said anyone who could afford it may wish to pay for the vaccine – not least because he hears regularly from new long Covid sufferers: 'Who wouldn't feel safer with boosted neutralising antibodies and T-cells?' He noted there is a spectrum of suffering, with people who are infected occasionally and mildly or non-symptomatically on one end, and on the other, those living with long Covid. There is also a third, under-researched, group in the middle of young or middle-aged people who get four to six reinfections per year, and may have to take several days off work each time. 'It's non-trivial and makes it quite hard to do your work,' he said. Although there is still hybrid immunity in the population because most people received several vaccines during the pandemic, there is a growing population of children who would have been too young to have received them at the time. The experts feared that growing vaccine hesitancy, which Williams described as 'one of the most pressing concerns' in public health, could have an impact on whether these children receive a jab or people turn up for their boosters. Another consideration, when it comes to building immunity, is the growing body of research suggesting that for several months after a Covid infection, people become more vulnerable to other infections and there can be lingering effects on the heart, cardiovascular system and the brain. 'We're only five years into this virus, there's a lot of question marks and unknowns,' said Williams.


Daily Mail
an hour ago
- Daily Mail
The hobby that adds 10 years to your lifespan with just 11 minutes a day
If the upcoming US Open isn't enough to get you in the tennis swing of things, then the sport's staggering fitness benefits might just sway you. Research suggests that playing the racquet sport could add 10 years to your lifespan with other benefits including improved heart health and muscle strength. What's more, health experts say that you don't have to spend hours on the court and just 11 minutes of tennis a day could get you fighting fit in no time. Natasha Tavares, a Colorado-based certified personal trainer and yoga instructor, told 'Tennis counts toward your 75 minutes of high-intensity aerobic exercise a week, which can either be split into sessions across the week. 'Alternatively, you could play one game while also enjoying other types of exercise. 'The rewards of tennis are endless, you're benefiting from being active and from spending time with friends, all of which can help with your short and long-term health.' The expert noted that playing tennis can quickly help to improve cardiovascular health and open up the arteries to improve blood flow, which can decrease blood pressure, reducing the risk of having a heart attack or stroke. 'Incorporating tennis into your routine helps strengthen your heart, which plays a vital role in your physical health, circulating blood, oxygen and nutrients throughout the body,' she said. 'It keeps your blood pressure down by improving the efficiency of the cardiovascular system.' The 2018 Copenhagen City Heart Study followed 8,577 people for 25 years in a bid to find out which sports are the best at boosting life expectancy. From the data collected, researchers found that tennis is the most beneficial sport when it comes to adding years to your life. The Danish researchers found that those who played tennis regularly added an average of 9.7 years to their lives compared to those who did not play the sport. This was well ahead of the second rated life-boosting sport which was badminton (6.2 years), followed by soccer (4.7 years), cycling (3.7 years) and swimming (3.4 years). The researchers suggested that the social aspect of tennis could play a role in positively impacting both mental and physical health. They concluded: 'The leisure-time sports that inherently involve more social interaction were associated with the best longevity—a finding that warrants further investigation'. According to the CDC, over 800,000 Americans either experience a heart attack or stroke each year, while about 375,000 people die from coronary artery disease annually. The American Heart Association recommends adults engage in moderate-intensity aerobic activity for about 150 minutes per week, including 75 minutes per week of vigorous aerobic activity or a combination of both, preferably spread throughout the week. About 138,000 Americans died from stroke in 2020, while one American dies of some form of heart disease every 33 seconds and the numbers are rising, especially among young people. But a 2016 BMJ study shows that playing tennis can reduce your risk of dying from heart disease by 56 percent compared to those who do not play the sport. Furthermore, the British and Australian researchers also found that playing tennis is linked with a 47 percent lower risk of dying prematurely from any cause. Additionally, Tavares claims that regularly playing a match can help build endurance in the body, which can improve muscle strength, tone the body and increase flexibility. Due to the repetitive movements involved while playing a match such as running, hitting the ball and maintaining grip strength, the sport helps build muscles in the legs, core, shoulders and arms. According to Harvard Health, an average 30-year-old will lose about a quarter of their muscle strength by age 70 and half of it by age 90. A 2018 Aging and Disease literature review also found that low levels of muscular fitness combined with insufficient dietary intake are major risk factors for illness and mortality from all causes. Researchers also noted that high muscular strength can reduce the risk of developing cardiovascular diseases, hypertension and Type 2 diabetes. However, engaging in a game of tennis can help preserve the ability to perform basic activities as well as maintain an active lifestyle. Tavares told the website: 'It also helps to build strength, particularly grip strength, which is essentially the amount of force you can exert when squeezing an object with your hand. In this case, the tennis racket handle. 'Grip strength has been linked with lifespan and overall health, particularly in older adults, mainly because it serves as a good indicator of your overall strength, which plays a key role in adults' well-being as they age. 'Maintaining strength can help prevent physical decline and support continued mobility.' Apart from this, experts also say that an hour-long game of singles tennis burns around 600 calories for men and 420 calories for women, which can help with weight loss.


The Guardian
an hour ago
- The Guardian
Daily pill helps patients lose 12% of body weight in early trial
A daily weight-loss pill has been shown to help patients lose about 12% of their body weight, according to the results of a clinical trial. The drug, made by the pharmaceutical company Eli Lilly, is a GLP-1 agonist – a type of medication that helps lower blood sugar levels, reduces appetite and slows digestion. More than 3,000 people took part in the 72-week study. Those who received the highest dose – 36mg of orforglipron – lost on average 12.4% of their body weight, compared with just 0.9% of the control group. The trial also showed other health benefits for users, including improvements to cholesterol, blood pressure and heart disease risk. The results come after Novo Nordisk's oral weight loss drug, which has been submitted for approval in the US, helped trial participants lose about 15% of their body weight. Eli Lilly manufactures Mounjaro, a once-a-week injection that contains the drug tirzepatide, which is also used to help improve blood sugar in people with type 2 diabetes. A weight loss pill could offer a more convenient and cheaper alternative – for both patients and the NHS – to injectable treatments that are being rolled out across England. The trial has not yet been peer reviewed and its results are preliminary. Kenneth Custer, the president of Eli Lilly, said: 'With orforglipron, we're working to transform obesity care by introducing a potential once-daily oral therapy that could support early intervention and long-term disease management, while offering a convenient alternative to injectable treatments. 'With these positive data in hand, we are now planning to submit orforglipron for regulatory review by year-end and are prepared for a global launch to address this urgent public health need.' Dr Simon Cork, a senior lecturer in physiology at Anglia Ruskin University, said although the preliminary results of the effectiveness were a 'positive step forward', they should be interpreted with caution. He said: 'It should be noted that their effects on weight loss are not as profound as that seen in injectable GLP-1 receptor agonists, such as Wegovy, with a lower percentage weight loss and fewer people achieving 10% weight loss at the highest dose. 'It should be noted that these are preliminary, non-peer reviewed results and we will need to see the full trial methodology and data before a more comprehensive analysis can be undertaken.'